Clinical trials
Hypertension trials in South Africa
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 10 |
| AstraZeneca | 5 |
| Novartis Pharmaceuticals | 4 |
| North-West University, South Africa | 3 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3 |
| GlaxoSmithKline | 2 |
| University of KwaZulu | 2 |
| Alnylam Pharmaceuticals | 1 |
| Arbor Pharmaceuticals, Inc. | 1 |
| Bayer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 47 |
| Diabetes Mellitus | 6 |
| Cardiovascular Diseases | 5 |
| Obesity | 5 |
| Renal Insufficiency, Chronic | 5 |
| Diabetes Mellitus, Type 2 | 3 |
| Heart Failure | 3 |
| Atrial Fibrillation | 2 |
| Dyslipidemias | 2 |
| Essential Hypertension | 2 |
Trials
Showing 26 to 47 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.